Department of Nutrition, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran; Nutrition and Food Security Research Center, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Clin Nutr ESPEN. 2021 Dec;46:54-59. doi: 10.1016/j.clnesp.2021.08.005. Epub 2021 Sep 4.
Polycystic ovary syndrome (PCOS) is a common endocrine disorder among reproductive-age women, and is associated with cardiovascular diseases as well as non-alcoholic fatty liver disease. The recent evidence suggested the beneficial effects of l-carnitine in women with PCOS.
The present study aimed to investigate the effect of l-carnitine supplementation on liver fat content and cardiometabolic outcomes in overweight/obese women with PCOS.
The present study was designed as a 12-week double-blind, randomized controlled clinical trial. Sixty-two overweight/obese women with PCOS were assigned into the treatment (received 1000 mg/d l-carnitine capsule) and the control (received placebo capsule) groups. The outcomes included lipid accumulation product (LAP), atherogenic index of plasma (AIP), atherogenic coefficient (AC) and Castelli II indices.
At the end of the trial, there was no significant difference between the treatment and the control groups in terms of LAP (-1.1 vs. -4.0; P = 0.45), AIP (0.0 vs. -0.09; P = 0.14), AC (-0.2 vs. -0.8; P = 0.06) and Castelli II index (-0.2 vs. -0.6; P = 0.07) after controlling the mean change of waist circumference.
l-carnitine supplementation for 12 weeks has no beneficial effect on liver fat content and cardiometabolic outcomes in overweight or obese women with PCOS.
Registered on 30 December 2019 at Iranian Registry of Clinical Trials IRCT20191016045131N1.
多囊卵巢综合征（PCOS）是生育期妇女常见的内分泌疾病，与心血管疾病以及非酒精性脂肪肝疾病有关。最近的证据表明左旋肉碱对 PCOS 妇女有益。
本研究旨在探讨左旋肉碱补充对超重/肥胖 PCOS 妇女肝脂肪含量和心脏代谢结局的影响。
本研究设计为 12 周双盲、随机对照临床试验。62 名超重/肥胖 PCOS 妇女被分配到治疗组（接受 1000mg/d 左旋肉碱胶囊）和对照组（接受安慰剂胶囊）。结局包括脂质蓄积产物（LAP）、血浆致动脉粥样硬化指数（AIP）、致动脉粥样硬化系数（AC）和 Castelli II 指数。
试验结束时，治疗组和对照组在 LAP（-1.1 与-4.0；P=0.45）、AIP（0.0 与-0.09；P=0.14）、AC（-0.2 与-0.8；P=0.06）和 Castelli II 指数（-0.2 与-0.6；P=0.07）方面无显著差异，校正腰围平均变化后。
左旋肉碱补充 12 周对超重或肥胖 PCOS 妇女的肝脂肪含量和心脏代谢结局没有有益影响。
于 2019 年 12 月 30 日在伊朗临床试验注册中心 IRCT20191016045131N1 注册。
